SK Plasma has partnered with Andong City to expand storage facilities for stable plasma fractionation product supply.
On July 15, SK Plasma announced the signing of a Memorandum of Understanding (MOU) worth approximately 12 billion KRW with Andong City at the city's communication office. This agreement aims to rapidly respond to the ever-changing global demand for blood products and establish a robust supply chain. Additionally, it is expected to stimulate the local economy and create new job opportunities.
The company plans to gradually enhance various production and operations facilities by 2027 on a 7,955.7 square meter site near the Andong Fractionation Center. This includes refrigeration facilities for storing raw plasma, cold storage for finished products, material warehouses, and office spaces. Alongside the expansion, SK Plasma intends to hire new personnel in related fields.
Since starting operations in 2018 at the factory built in the Andong Gyeongbuk Bio Industry Complex in 2015, SK Plasma has been processing 600,000 liters of plasma annually. The company supplies key blood products like albumin and immunoglobulin domestically and internationally.
Andong City views this investment as a chance to enhance the competitiveness of its local bioindustry. Kwon Ki-chang, Mayor of Andong City, stated, "SK Plasma's increased investment demonstrates the growth potential of the Andong bio cluster. We will continue to cultivate a business-friendly environment and provide administrative support.”
Kim Seung-joo, CEO of SK Plasma, commented, "This facility expansion represents a crucial advancement in quickly adapting to the unpredictable changes in market demand and bolstering the reliable production and supply foundation of blood products. We aim to create a sustainable bioecosystem, growing alongside the local community with Andong City.”
Meanwhile, SK Plasma is also accelerating its overseas expansion. The company is constructing a plasma fractionation center in Karawang, Indonesia, capable of processing 600,000 liters annually, targeting operation in the fourth quarter of 2026. Until operations commence, the plasma collected in Indonesia will be processed at the Andong facility to minimize supply gaps.
